First safety test of a cell therapy placed inside the brain
Original title: Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a first, small safety study in people, so it is far from being something a doctor can offer.
The short version
A small first study put an immune cell treatment straight into the brain, and patients handled it well.
What was studied. Doctors tested a treatment called SCOPE-T in 25 people with brain metastases or glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that had stopped responding to other care. It is a low dose of a drug called pemetrexed, followed by immune cells and a protein called interleukin 2, all given into the brain through a small implanted port.
What they found. Nineteen patients finished at least one round of treatment. 17 of them got the highest dose of cells that was tested. The treatment was well tolerated. There were no side effects from the treatment worse than mild or moderate, and the most common ones were short lived fever and headache. Early scans and checkups suggested the disease held steady in the patients they could measure.
What this means, and what it doesn't
What it could mean: This is an early sign that giving this cell therapy directly into the brain is doable and safe enough to keep studying. It may become an option to test for people who cannot have surgery, radiation, or drugs that travel through the whole body. It is not something you can ask for as standard care today.
What it doesn't mean: This does not mean a cure. It was a phase 1 study, which is the first stage of testing in people. Phase 1 mainly asks if a treatment is safe, not whether it helps people live longer. Only 25 people took part, and there was no comparison group. The researchers themselves say the results are exploratory. Much larger studies would be needed before this could become regular care.
Source: PubMed, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.